The wide variety of clinical manifestations of the genetic syndrome neurofibromatosis type 1
(NF1) are driven by overactivation of the RAS pathway. Mitogen-activated protein kinase …

Juvenile myelomonocytic leukemia (JMML) is a typically aggressive myeloid neoplasm of
childhood that is clinically characterized by overproduction of monocytic cells that can …

The dysregulation of the JAK/STAT pathway drives the pathogenesis of myelofibrosis (MF).
Recently, several JAK inhibitors (JAKis) have been developed for treating MF. Select …

We previously demonstrated that a subset of acute myeloid leukemia (AML) patients with
concurrent RAS pathway and TP53 mutations have an extremely poor prognosis and that …

In the 2008 WHO classification, chronic myeloid malignancies that share both
myelodysplastic and myeloproliferative features define the myelodysplastic …

Myelodysplastic syndromes/myeloproliferative neoplasms (MDS/MPN) are aggressive
myeloid malignancies recognized as a distinct category owing to their unique combination of …

Myeloproliferative neoplasms (MPN) show dysregulated JAK2 signaling. JAK2 inhibitors
provide clinical benefits, but compensatory activation of MAPK pathway signaling impedes …

Myelodysplastic syndrome (MDS) is a clonal bone marrow disorder, typically of older adults,
which is characterized by ineffective hematopoiesis, peripheral blood cytopenias and risk of …

NRAS Q61 mutations are prevalent in advanced/relapsed multiple myeloma (MM) and
correlate with poor patient outcomes. Thus, we generated a novel MM model by …

Background Relapsed and refractory (R/R) acute myeloid leukemia (AML) continues to be a
therapeutic challenge with poor outcomes. Dysregulation of the mitogen-activated protein …